Sucampo Pharma Europe Receives Marketing Authorization for Amitiza(R) in Switzerland for Treatment of Chronic Idiopathic Constipation  
11/20/2009 8:55:40 AM

Bookmark and Share

BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC).